Tuesday, December 23, 2025
Home Blog Page 1116

Largest Marijuana Park East Of The Mississippi Happening In Michigan

It sounds like an autumnal offshoot of Disneyland, and for some it kind of is, but Michigan’s Harvest Park in is on track to become an epic medical marijuana facility, creating hundreds of cannabis-related jobs in its wake.

Jeff Donahue, Harvest Park Development LLC’s managing director, tells Lansing State Journal he expects to see a creation of  “ancillary businesses” that specialize in fields like packaging, machine operation and data analytics.

The 63-acres of Harvest Park, located in Windsor Township in Eaton County, is portioned off into 10 lots, each for sale. And according to the LSJ, “land will be available to marijuana cultivators, processors, secure transporters, testing labs and suppliers. All will need approval from the township and state to operate. Two of the lots are already under contract with the company.”

Says Donahue, “I think the location is perfect, It’s an area ripe for development.”

Michigan state law allows cities and townships to make the call on whether or not to allow marijuana businesses — and which types — to operate.

This new park could be a financial windfall for Windsor Township, with experts predicting revenues of more than $700 million in medical marijuana annually, should it ever become fully legal.

Harvest Park is targeting spring as their official opening.

WATCH: Microsoft Employees Can Now Work From A Giant Tree House

Because free beverages, on-site restaurants and unlimited foosball isn’t enough to get the average tech worker through their day, Microsoft has unveiled a luxury tree house built for its employees who need to get work done, but also be inspired by the wilderness and gentle breezes of nature.

The roomy tree house —complete with wifi and electrical outlets — is located among the 500 acres of forest that surrounds Microsoft headquarters in Redmond, Washington (about a half hour east of Seattle). And while reading a description of the “outdoor meeting spaces” on the company’s blog, one gets the sense they’re in the presence of Henry David Thoreau.

To get to Microsoft’s most unexpected new meeting space, embark on a leisurely outdoor stroll up a planked, accessible switchback ramp. At the top, a secure wooden gate swings open to reveal a deck suspended by timber beams and cables. A minty pine perfume infuses the air. Two angled cedar awnings jut out from tree trunks, protecting employees from the elements.

Whomever wrote this post is definitely angling for a book deal.

Aloft, the usual corporate sounds of clicking doors, conference calls, and heels on concrete melt away. A fall wind sweeps through emerald branches. Every once in a while, a pinecone drops to the deck with a soft thud. A sudden ruckus breaks the gentle morning hush: a squirrel scrambling for breakfast charges across the arms of nearby hemlock and western red cedar.

It gets better. According to the blog, the treehouse is one of three new branch-based meeting spaces created by Pete Nelson of “Treehouse Masters” on Animal Planet. He reportedly kicked off the project by spending his first day on the site “connecting with the trees” for hours, according to Microsoft’s Bret Boulter, who headed up the project. He says the treehouse was built to “flex and expand as the trees grow” with an expected lifespan of at least 20 years.

The largest part of the three-pronged treehouse sits 12-feet off the ground and features “charred-wood walls and a soaring ceiling with a round skylight that lets in just a bubble of blue. It’s more Hobbit than HQ, with cinnamon-colored shingles and a gingerbread-house feel.” An elevated roost called the Crow’s Nest and a third sheltered lounge space (opening later this year) round out the trifecta.

And while this is all incredibly cool, Microsoft had an actual beneficial reason for building its adult tree house: scientific evidence shows working outdoors improves creativity, focus, and happiness. All that’s missing are the hot dogs and marshmallows.

Tom Marino Won’t Be Drug Czar: Why Marijuana Enthusiasts Are Happy

Rep. Tom Marino, President Donald Trump’s controversial pick to be America’s drug czar, has removed his name out of consideration after an investigation from The Washington Post and CBS News revealed he played a role in undermining the DEA’s ability to crack down on opioid abuse.

The scandal, which broke Sunday, culminated in Marino’s withdrawal on Tuesday. This marks the second time the well-known drug warrior abruptly ended his nomination. In May, citing family health issues, walked away after Trump’s nomination.

On Tuesday, Marino released this statement:

“As a former prosecutor who has dedicated my life to aggressive and faithful enforcement of our laws, I have reached the difficult decision that the best course of action is to remove the distraction my nomination has created to the utterly vital mission of this premier agency.

With Marino out of the picture, the future of the Office of National Drug Control Policy remains fuzzy. As America grapples with an opioid overdose epidemic — CDC data shows that overdose deaths climbed to 64,070 in 2016 (up more than 11,000 from 2015) — there is a lack of leadership on the issue.

As Americans For Safe Access writes:

With Rep. Marino withdrawing, the country’s leadership on national drug policy remains unclear:

  • ONDCP does not have a permanent person in role of Drug Czar

  • Department of Health and Human Services is without a Secretary of Health after Tom Price’s resignation

  • The DEA only has an acting director, and

  • The President’s Commission on Combating Addiction and the Opioid Crisis has continued to delay and postpone its meetings.

Trump has promised he would declare a national emergency next week to help solve the crisis, but he has made that promise before with no results. Despite the lack of leadership, most cannabis advocated were pleased with Marino’s withdrawal. The Drug Policy Alliance gave Marino an F in its 2016 voter guide:

“The Trump administration has escalated the war on drugs, ignoring overwhelming evidence that it’s deeply unpopular and staggeringly counterproductive,” said Grant Smith, deputy director of national affairs with the Drug Policy Alliance. “The next drug czar should resist failed drug war tactics and instead prioritize health-based interventions that reduce drug related harm and save lives.”

As the Washington Post‘s Christopher Ingraham writes:

Marino’s congressional voting record is that of a hard-liner on marijuana issues, and he recently said that he’d like to put nonviolent drug offenders in some sort of “hospital-slash-prison.”

In Congress, Marino voted multiple times against a bipartisan measure to prevent the Justice Department from going after state-legal medical marijuana businesses. (The measure ultimately passed.)

Similarly, he voted against a measure to allow Veterans Affairs doctors to recommend medical marijuana to their patients, as well as against a separate measure to loosen federal restrictions on hemp, a non-psychoactive variant of the cannabis plant with potential industrial applications.

 

How Comprehensive Cannabis Consulting Is Making Cannabis Safer

On November 2nd, Nic Easley, will speak at Kahner Global’s 2nd Annual Cannabis Private Investment Summit in Toronto. This event gathers industry leaders and investors for a day of collaboration and networking.  

Comprehensive Cannabis Consulting – a.k.a. 3C Consulting, LLC. – is a team of researchers, agriculturists and business professionals that focus on building cannabis empires.

The team members of 3C Consulting, LLC., which is related to Multiverse Capital, have decades of experience in the cannabis sector, and not just in cultivation. Every aspect of business related to cannabis is high priority to 3C Consulting, LLC., and it’s paid off.

CEO Nic Easley is a veteran of the United States Air Force, where he was a romance language crypto linguist. He carries with him over 15 years of experience in the commercial cannabis realm and holds degrees in biology and environmental studies.

Easley oversees the production of high-quality organically grown cannabis. He also advises on profitability and sustainability with a focus on consistently raise the industry bar. He helps his clients enter the cannabis space in big ways, showcasing both cannabis and hemp and their amazing potentials and benefits to the planet.

As the industry grew in Colorado, Easley saw issues grow too, especially pesticide problems inside the grows. “In 2012, we saw marijuana was about to go legal, and decided it was time to go big.” They got right on it, “Not to just make money in the green rush, which happened kind of by accident, but to help the industry work better.” expounded Easley.

3C Consulting, LLC. started working in other states and began an extraction division. They make sure extraction is safe and efficient for the 22 medical states and seven countries they work within. They’ve started over 40 joint ventures to date.

Things have been advancing rapidly for 3C Consulting, LLC. When Easley spoke with The Fresh Toast, he had just returned from Denmark where hot new cannabis opportunities abound. They’d also qualified for one of the top 10 licenses in Germany. “This knowledge is hot off the press,” said Easley, “and a lot of people need it.

Growing by leaps and bounds in the last three years 3C continues to be an ethical company that strives to do the right thing environmentally while lowering the cost of production and following EPA, USDA FDA, OSHA guidelines.

Pennsylvania Gives Green Light For First Marijuana Crop

Finally! Pennsylvania’s medical marijuana program took a giant step forward as a licensed grower and processor of the herb in northwestern part of the commonwealth became the first to be approved.

The Pennsylvania Department of Health today approved Cresco Yeltrah to begin farming medical marijuana at its Jefferson County location, making it the first facility to be deemed fully operational in Pennsylvania’s medical marijuana program.

“Every day we hear from patients who are desperately waiting for medical marijuana to help alleviate the symptoms of their serious medical conditions,” Gov. Tom Wolf said in a press release. “My message to them today is that Pennsylvania’s medical marijuana program is moving forward and we will have medication to them sometime in 2018. Cresco Yeltrah will now be able to grow medical marijuana, making sure that patients will not have to wait much longer.”

Cresco Yeltrah underwent several inspections from the Department of Health. It also is fully integrated with the seed-to-sale tracking system.

“In the coming weeks, we expect the 11 other grower/processors to be ready to grow and process medical marijuana,” Acting Health Secretary and Physician General Dr. Rachel Levine said.  “We are working with them, as well as the dispensaries, to ensure the program stays on track.  Patients are our first priority, and we want to get medication to them as safely and efficiently as possible.”

Cresco Yeltrah said it will grow more than 30 genetic strains and will produce pharmaceutical-grade marijuana products such as vapor oils, transdermal patches and pills. The Pennsylvania medical marijuana laws do not allow for flower or herb. Cannabis must be in the form of a pill, oil, cream, ointment, tincture of transdermal patch.

Construction on converting the 40,000-plus-square-foot facility began immediately after the permit was awarded, according to the company. “All of the required mechanisms are in place to ensure the safety and security as required by law,” the company said in a press release. “With a controlled cultivation environment, a full grow cycle takes approximately 120 days which will allow for their complete line of products to be available for patients statewide in February 2018.”

Pennsylvania’s medical marijuana allows patients with these 17 qualifying conditions:

  • Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease)
  • Autism
  • Cancer
  • Crohn’s Disease
  • Damage to the nervous tissue of the spinal cord with objective neurological indication of intractable spasticity
  • Epilepsy
  • Glaucoma
  • HIV/AIDS
  • Huntington’s Disease
  • Inflammatory Bowel Disease
  • Intractable Seizures
  • Multiple Sclerosis
  • Neuropathies
  • Parkinson’s Disease
  • Post-traumatic Stress Disorder
  • Severe chronic or intractable pain
  • Sickle Cell Anemia

5 Cannabis Stocks We Are Watching Today: October 19, 2017

Out of over 200 marijuana stocks, there’s five that we’re going to be watching as the markets open due to breaking news out this morning.

Here’s five cannabis companies to watch today including 22nd Century Group Inc. (NYSE:XXII) and more.

22nd Century Group Inc. (NYSE:XXII)

Today, the Johns Hopkins Bloomberg School of Public Health will host the public health community’s first opportunity to discuss the groundbreaking vision of the US Food and Drug Administration to reduce nicotine in cigarettes to non-addictive levels. This is expected to move shares of XXII given the company’s substantial patent portfolio surrounding their very low nicotine tobacco/cigarettes.

CannaRoyalty Corp. (CSE:CRZ) (OTC:CNNRF)

This morning, CannaRoyalty Corp. announced the official launch of its first CR Brands product in California through CannaRoyalty investee River Collective, California’s largest cannabis distributor. The company has started selling Soul Sugar Kitchen gourmet-edibles through River’s distribution network of 677 dispensaries in California, and is on track to launch GreenRock Botanicals premium vape pens this quarter.

Cronos Group Inc. (TSXV:MJN) (OTC:PRMCF)

This morning, Cronos Group Inc. announced that it has entered into a letter of engagement with PI Financial Corp. as sole lead underwriter. PI has agreed to purchase for re-sale 4,761,905 common shares of the company, on a “bought deal” basis pursuant to the filing of a short form prospectus, subject to all required regulatory approvals, at a price per share of $3.15 CAD, for total gross proceeds of $15,000,000.75 CAD, equivalent to roughly $12,016,500.60 USD at current foreign exchange rates.

Marapharm Ventures Inc. (CSE:MDM) (OTC:MRPHF)

This morning, Marapharm Ventures Inc. announced that it has today filed an early warning report advising that it has purchased a total of 1,500,000 units of Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) at a purchase price of $0.28 CAD per unit, each unit consisting of one common share in the share capital of the issuer and one common share purchase warrant of the issuer, exercisable at a price of $0.45 CAD per common share for a period of 18 months.

Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF)

This morning, Marapharm Ventures Inc. announced that it has today filed an early warning report advising that it has purchased a total of 1,500,000 units of Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) at a purchase price of $0.28 CAD per unit, each unit consisting of one common share in the share capital of the issuer and one common share purchase warrant of the issuer, exercisable at a price of $0.45 CAD per common share for a period of 18 months.

This story was originally published in The Daily Marijuana Observer. You can connect with them on on social media via Facebook, Twitter, StockTwits, YouTube, and Instagram.

After The Smoke Clears: What The California Fires Mean For Marijuana

 The October firestorms raging in Northern California have incinerated nearly a quarter million acres and displaced more than 100,000 residents. Heavy smoke has blanketed the skies in the nine-county San Francisco Bay Area, poisoning the air to an unprecedented degree and prompting air quality alerts and health advisories throughout the region.

“We have never recorded higher levels of air pollution in the Bay Area,” said air district spokeswoman Kristine Roselius.

While a limited number of deaths have been reported thus far, the public health impacts of this disaster will be felt for many months to come. This is not a typical wildfire; in Santa Rosa, flames have melted gas pipes, power lines, even a cellphone tower. The blaze has scorched thousands of homes and cars, releasing metals into the air. Rubber, fiberglass, paint, and electrical equipment burn to uncommon and highly dangerous toxins, such as dioxins and other biphenyl compounds.

Poisons contained in the smoke will slowly fall from the air and be absorbed by plants and the watershed, contaminating agricultural crops, including those in the Emerald Triangle, America’s cannabis breadbasket. The timing couldn’t have been worse for cannabis farmers as these fires came at the start of harvest season. Cannabis producers and consumers need to be cautious about the chemicals that could accumulate.

There are three common ways that toxins and carcinogens in smoke can be removed from the atmosphere:

  • Volatile chemicals like formaldehyde and carbon monoxide will dissipate by reacting with trace gasses in the air, perturbing the concentration of ozone and other gasses. When carbon monoxide reacts with oxygen radicals, for example, it converts to carbon dioxide.
  • Hardier chemicals may be removed from the sky by wet deposition, whereby rain pulls pollution out of the atmosphere. But that requires precipitation. And if it rains, highly toxic run-off will pollute the watershed.
  • Other chemicals will simply fall from the sky and deposit onto plants, soil, and other solid surfaces. These compounds include benzene, polycyclic aromatic hydrocarbons, and dioxins. The chemicals that settle on cannabis or nearby water and soil can be absorbed by the plant and passed on to the consumer. Cannabis, a bioaccumulator, will uptake heavy metals from the soil that have deposited on the ground.

While these toxins can pose serious health hazards, it is important not to exaggerate harms. Cannabis smoke (even from untainted, organically grown cannabis) also contains carcinogens, but smoking marijuana does not increase the risk of oral and lung cancers—possibly because THCCBD, and other plant cannabinoids exert a direct anti-tumor action against oral and lung cancer.

Another factor that may mitigate harm from inhaled cannabis smoke is the inhibition of a group of enzymes called CYP1A. Polycyclic aromatic hydrocarbons become more carcinogenic when metabolized by CYP1A enzymes in the body: By inhibiting CYP1A in the lungs, cannabinoids could reduce the activation of these carcinogens.

In cannabis smoke, roughly 0.5% of the plant material converts to polycyclic aromatic hydrocarbons. That is 5000 parts per million by weight (ppm). Carcinogenicity of aromatic hydrocarbons is usually discussed at concentrations on the order of 10 ppm. It remains to be seen if toxins deposited by the fires will be greater than the concentrations normally found in cannabis smoke. If not, then this cannabis is likely safe to consume (though it may require a warning under prop 65). To reduce further toxicity, it would be best for people to avoid smoking cannabis tainted by the wildfires: vaporization and ingestion are alternatives.

But consumers should also be aware that extraction processes (including butane, ethanol, and CO2) may concentrate these unwanted chemicals, though this is not precisely known. Cannabis producers and consumers should make sure, if possible, that any lab tests apply to the final product, not just the plant material that was used for extraction.

Accurate testing is paramount. Unfortunately, some cannabis labs have a record of providing results before they have validated their methods and can be certain that their numbers are correct. (Validation involves spiking precise amounts of contaminants into clean cannabis samples to ensure that accurate results are obtained.)

Several fire-generated toxins that may be deposited on cannabis crops—including benzene and toluene—are on the list of regulated solvents that California labs will likely have to quantify in cannabis products as of 2018. In preparation for the upcoming regulations, analytical labs may have already validated methods for detecting these compounds.

But other, less common toxins, such as benzopyrenes and polychlorinated dibenzo dioxins (PCDDs; sometimes simply called dioxins), are not included in the new regulations. Dioxins are particularly important: they are formed when chlorinated plastics burn, such as PVC pipes. One kind of dioxin, which is called TCDD, disrupts endocrine, immune, and reproductive systems as well as fetal development. It is also a carcinogen at larger concentrations. (TCDD was also a contaminant in Agent Orange, a chemical weapon created by Monsanto and used in the Vietnam war.)

Whether mandated by state regulations or not, cannabis labs should also test for these compounds. Thus far, however, cannabis labs have not validated testing procedures for these compounds.

Another concern: helicopters and planes have been dumping tons of fire-repellant in an effort to contain the fires. The fire-repellant used, another Monsanto-designed product called Phos-Chek, may also have adverse health consequences. One of the main constituents of Phos-Chek is ammonium salt. Ammonium is a fertilizer: If absorbed through the plant, it is unlikely to be toxic, but smoking or vaporizing ammonium stuck on cannabis resin should be avoided.

Project CBD hopes that some lab in California will validate methods and offer tests to detect the major contaminants that result from the wildfires. We expect these will include benzene, toluene, benzopyrenes, and heavy metals, as well as some dioxins and polychlorinated biphenyls.

Adrian Devitt-Lee, a Project CBD contributing writer, is a senior research associate with CannaCraft.

This story originally was published by Project CBD, a California-based nonprofit dedicated to promoting and publicizing research into the medical uses of cannabidiol and other components of the cannabis plant. 

Taking It To The Next Level: A Look Inside Extreme Cannabis

On November 2nd, Chris Schnarr of Extreme Cannabis, will speak at Kahner Global’s 2nd Annual Cannabis Private Investment Summit in Toronto. This event gathers industry leaders and investors for a day of collaboration and networking.

Extreme Cannabis is a Canadian investment fund and accelerator launched by Chris Schnarr and partners under the umbrella group Extreme Venture Partners. Their aim is to make investments in the ancillary sector of the cannabis space, which is what they see as this rapidly emerging second wave.

As entrepreneurs step up and fill in the additional needs in the industry—from operations to software to product efficiency and inventory management, content platforms, mobile apps, devices, testing systems, etc.—Extreme Cannabis puts the funds in place. The team from Extreme Venture Partners, are, as Schnarr says, “Arguably the most successful seed stage and early stage investors in Canada.”

Schnarr wants to avoid the standardized graphs and charts for analysis and instead tell a story about the cannabis plant, providing information that isn’t common knowledge. He plans to literally look back on a global scale over five millennia. “It has a rich history and an amazing story, so I want to look at that and talk to the folks about that. We’ll also be looking at understanding the plant itself, what’s in it, why it works, understanding the compounds and effects to the human body… What does it all mean from a disease perspective and then have a look at the results and where the industry is today.”

Another pet project for Schnarr is Canopy Growth. They were looking for some more public company experience, an area where Schnarr has a reasonably deep portfolio that is 20 years strong. In those days, the only thing was the licensed producers, there was nowhere else to go, but Schnarr saw it as a great opportunity and says, “I feel very blessed to be part of it.”

Canopy Growth is the largest producer of legal cannabis in the world and the largest cannabis company by market cap, so it’s been an amazing experience for Schnarr and he’s learned “a ton” along the way. He also sits on the board of their sister company, Canopy Health innovations, which is more focused on the development of very specific uses for the drug, “and I’ve learned so much,” he told The Fresh Toast, his grin audible.

One of the things he’s learned about are that different companies are taking different approaches to medicating with cannabis. Some are isolating cannabinoids while others swear by full-plant extract.

“There’s a mix of companies doing both,” said Schnarr, “It’s a very rich plant, with different active components inside the plant. There are different companies who are trying to pull out one particular constituent, for example CBD, cannabidiol, and get it in a very isolated fashion for a variety of conditions, pain would be an example, and there are others who are more trying to take advantage of the broad spectrum of the plant itself and what you sometimes hear called the entourage effect where somehow mother nature has crafted this symphony inside the plant where the different compounds and constituents, where they work together seem to be more effective, seem to have an enhanced effect rather than pulling it all apart and using individual pieces.”

Time will likely tell us that there’s going to be success and viability in both approaches, and Schnarr’s work with Extreme Cannabis, Canopy Growth and Canopy Health Innovations are sure to turn over new leaves and lend to a hearty discussion at the Cannabis Private Investment Summit.

Jeff Sessions Would Like To See More MMJ Growers For Research

When Jeff Sessions testified in front of the Senate Judiciary Committee on October 18, cannabis activists across the nation waited with bated breath to see if the topic of marijuana would come up. When it did, Attorney General Jeff Sessions surprised us all.

Rather than his normal anti-pot rhetoric, Sessions said he wants to see “more competition” among medical cannabis growers who are growing for research purposes. After which, Sen. Orrin Hatch, Utah (R), who is opposed to broad legalization, asked to “clarify” the DOJ’s position on providing these researchers with medical grade cannabis.

Sessions reiterated that he thought that competition was healthy, though he wasn’t sure that the given number of 26 needed to be in effect. Hatch in turn reiterated that he is not for the broad legalization of cannabis, but saw the logic in researching both the medical benefits and potential pitfalls of the plant.

Even the DEA last year said that they planned on increasing the supply of medical cannabis to researchers. Prior to that, the only researchable weed came from a facility at the University of Mississippi, but patients and advocates constantly complained about quality. The new variety of cannabis flowers should provide more comprehensive results.

Sessions did also say that he wants to limit the expansion and that he’d prefer the Justice Department didn’t approve all 26 applications. He also raised questions about how much it all was going to cost the DEA to observe operations.

“Each one of those has to be supervised by the DEA, and I have raised questions about how many and let’s be sure we’re doing this in the right way because it costs a lot of money to supervise these,” Sessions said.

Both medical and recreational marijuana are still illegal at the federal level with their Schedule I status, but that hasn’t stopped 29 states and the District of Columbia to pass some form of medical cannabis legislation, with overarching positive results ranging from wellness to monetary benefits.

Medical marijuana is currently protected from the DOJ by the Rohrabacher-Farr Amendment, which prevents federal crackdowns on medical states that comply. However, it’s unclear that the amendment will continue to stand and renew after its initial expiration and it’s also unclear if Sessions has plans to come down on recreational. Time will tell, but for now, Sessions’ first pretty positive marijuana statement deserves at least raised, hopeful eyebrows.

Pennywise The Clown Is THE Halloween Pumpkin Carving

Pumpkin carving has evolved into a minor league sport in recent years. Thanks to the advent of social media, everyone can share their pumpkin creations and propose one carving is better than the other. And every year the It pop culture icons of the years serve as inspiration for carvings. This year the It icon is, well, the movie It. Specifically Pennywise the clown is THE Halloween pumpkin carving this year.

Related: 5 Pumpkin Masks That Are Perfect For Dewy Fall Skin

Now, Pennywise is not a very nice clown. He’s literally the incarnation of pure evil manifested to showcase your deepest fears. But thanks to Bill Skarsgård’s sensational portrayal of the clown, that pure evil captivated dozens to show off their interpretation for Halloween.

Check out some of our favorite Pennywise pumpkin carvings this year.

The Faithful Adaptation

The Painting

The Light Show

https://twitter.com/lightpullsmein/status/918995644328620033

The “Do It For The Snap”

The Red, White, And Blood All Over

https://twitter.com/jolieee85/status/919004442200068096

 The Dad Joke

The “You’ll Float, Too”

https://twitter.com/corinhardy/status/918000916749467648

The Picasso

The OMG THIS IS DOPE

In the Stephen King novel IT, the character is a shapeshifting monster who usually takes the form of Pennywise the Dancing Clown, originating in a void containing and surrounding the Universe—a place referred to in the novel as the “Macroverse”.

WIth the look Pennywise the clown is THE Halloween pumpkin carving for the next few years!

Don't Miss Your Weekly Dose of The Fresh Toast.

Stay informed with exclusive news briefs delivered directly to your inbox every Friday.

We respect your privacy. Unsubscribe anytime.